HPM Web Site

  • HPM Web Site

Get Updates via E-mail

  • Enter your email address to automatically receive new posts to the FDA Law Blog via e-mail.

    Delivered by FeedBurner

 Subscribe in a reader


  • FDA Law Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of FDA Law Blog does not create an attorney-client relationship. FDA Law Blog is the blog of Hyman, Phelps & McNamara, P.C. (“HPM”) and it is intended primarily for other attorneys and regulatory professionals. No part of FDA Law Blog --whether information, commentary, or other-- may be attributed to HPM's clients. Readers should be aware that HPM represents many companies in the food, drug, medical device, and health care industries, and therefore FDA Law Blog may occasionally report on news that relates to HPM clients. FDA Law Blog will always strive to be unbiased in its reporting. All information on FDA Law Blog should be double-checked for its accuracy and current applicability.

    Copyright 2011 Hyman, Phelps & McNamara, P.C.

Awards & Honors

« District Court Rules on Jurisdiction and Non-Final Agency Action | Main | FTC Announces Workshop and Study on Follow-On Biologic Patent and Non-Patent Exclusivity Issues »

August 27, 2008


TrackBack URL for this entry:

Listed below are links to weblogs that reference DEA Actions Upheld by D.C. Court of Appeals:

» "Mere unevenness in the application of a sanction will not render its application in a particular case unwarranted in law" from Administrative Law Prof Blog
The FDA Law Blog points out a recent D.C. Circuit opinion confirming that under the Administrative Procedure Act (APA) an agency’s choice of sanction will be overturned only if it is “arbitrary, capricious, an abuse of discretion, or otherwise not [Read More]


The comments to this entry are closed.

180-Day Exclusivity Tracker

Citizen Petition Tracker

REMS Tracker

Legislation Tracker